MétaCan
Menu
Retour à la cohorte
Enregistrement W4281624688 · doi:10.1200/jco.2022.40.17_suppl.lba501

LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T<sub>1</sub>N<sub>0</sub> luminal A breast cancer (BC).

2022· article· en· W4281624688 sur OpenAlexaffabout
Timothy J. Whelan, Sally Smith, Torsten O. Nielsen, Sameer Parpia, Anthony Fyles, Anita Bane, Fei‐Fei Liu, L. Grimard, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Eileen Rakovitch, Valérie Théberge, Anna Marie Mulligan, Mohamed Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory R. Pond, Mark N. Levine

Notice bibliographique

RevueJournal of Clinical Oncology · 2022
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueBreast Cancer Treatment Studies
Établissements canadiensMcGill University Health CentreUniversity of ManitobaSunnybrook Health Science CentreUniversity of British ColumbiaCentre Hospitalier Universitaire de SherbrookeHôtel-Dieu de QuébecBC Cancer AgencyNortheast Cancer CentreRoyal Victoria Regional Health CentreHealth Sciences NorthMcMaster UniversityToronto General HospitalPrincess Margaret Cancer CentreCancerCare ManitobaHealth Sciences CentreOttawa Regional Cancer FoundationOntario Clinical Oncology Group
Organismes subventionnairesnon disponible
Mots-clésMedicineBreast cancerBreast-conserving surgeryInternal medicineRadiation therapyOncologyClinical trialProspective cohort studyCohortCancerAdjuvantGynecologyMastectomy

Résumé

récupéré en direct d'OpenAlex

LBA501 Background: Adjuvant breast RT is usually prescribed following BCS to reduce the risk of local recurrence (LR). However, this treatment is inconvenient, costly, and associated with acute and late toxicity. Traditional clinical pathological factors (CPFs) alone are limited in their ability to identify women with a low enough risk of LR to omit RT. Molecular defined intrinsic subtypes of BC provide additional prognostic information with luminal A having the lowest risk of recurrence. A retrospective analysis of a previous trial suggested that women &gt;60 years with luminal A grade 1-2 T 1 N 0 BC treated by BCS and endocrine therapy alone had a low rate of LR ( JCO 2015; 33:2035). The utility of identifying luminal A subtype combined with CPFs has not been prospectively evaluated for its ability to guide RT decision-making. Methods: A prospective multicenter cohort study was performed. Eligibility criteria were: women ≥ 55 years; having undergone BCS for grade 1-2 T 1 N 0 BC; ≥ 1mm margins of excision; luminal A subtype (defined as: ER ≥ 1%, PR&gt;20%, HER2 negative and Ki67 ≤ 13.25%); and treated with adjuvant endocrine therapy. ER, PR and HER2 were performed locally as per ASCO guidelines. Patients meeting clinical eligibility with ER ≥ 1%, PR&gt;20%, HER2 negative BC were registered and had Ki67 immunohistochemistry performed centrally in one of three Canadian laboratories using International Ki67 Working Group methods. Proficiency testing between laboratories was performed yearly. Patients with Ki67 ≤ 13.25% were enrolled in the trial and were assigned to not receive RT. The primary outcome was LR defined as time from enrollment to any invasive or non-invasive cancer in the ipsilateral breast. Assuming a 5-year LR rate of 3.5%, 500 patients were required to show that the upper bound of a two sided 90% (one-sided 95%) confidence interval (CI) was &lt;5%. Patients were followed every six months for the first two years and then yearly. The probability of LR was estimated using the cumulative incidence function with death as a competing risk. Secondary outcomes were contralateral BC; relapse free survival (RFS) based on any recurrence; disease free survival (DFS) based on any recurrence, second cancer or death; and overall survival (OS). Results: From August 2013 to July 2017, 501 of 727 registered patients from 26 centers had a Ki67 ≤ 13.25% and were enrolled. Median follow-up was 5 years. Median age was 67 and 442 (88%) patients were &lt;75 years. Median tumor size was 1.1 cm. The 5-year rate of LR satisfied our pre-specified boundary (see Table). Conclusions: Women ≥ 55 years with grade 1-2 T 1 N 0 luminal A BC following BCS treated with endocrine therapy alone had very low rates of LR at 5 years and are candidates for omission of RT. Clinical trial information: NCT01791829. [Table: see text]

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,005
score de la tête « metaresearch » (Gemma)0,001
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMéta-épidémiologie (sens strict)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,272
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0050,001
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0020,001
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,037
Tête enseignante GPT0,371
Écart entre enseignants0,334 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations45
Publié2022
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueJournal of Clinical OncologyMême sujetBreast Cancer Treatment StudiesTravaux en français237 207